linjc16/ctgov huggingface dataset:
Magnetic Resonance Imaging of Human Biometrics

Study Overview
=================
Brief Summary
-----------------
The primary objective is to collect high quality MRI data (un-processed or processed) from participating subjects for Medtronic research purposes.

Official Title
-----------------
Magnetic Resonance Imaging of Human Biometrics

Conditions
-----------------
Volunteers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is at least 18 years of age Subject is willing and able to undergo study requirements Exclusion Criteria: Subject has a medical condition that precludes the subject from participation Subject has any magnetizable foreign object (e.g. jewelry) which cannot be removed for the duration of the study Subject is claustrophobic Subject is unable to stand without assistance Subject requires sedation for MRI scans Subject is implanted with non-Magnetic Resonance conditional or other medical device: Non-MRI conditional pacemaker, Implantable Cardiac Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT), or an implantable hemodynamic monitor Metal clips (i.e. brain aneurysm clip) Artificial heart valve Implanted neural stimulator Gastric capsule camera Swan Ganz catheter Stent Inferior Vena Cava (IVC) filter Orthopedic implant Eye prosthesis Vascular access port Penile prosthesis Intrauterine device Subject has a cochlear implant, middle ear prosthesis, or has had ear surgery Subject has ocular foreign bodies (i.e. metal shavings) Subject has any type of device held in place by a magnet (i.e. dentures) Subject has an insulin pump Subject has metal shrapnel Subject is pregnant or lactating Subject has magnetizable implant Subject requires legally authorized representative to sign Patient Informed Consent (PIC)/ Informed Consent (IC) form Subject has other contraindication for an MRI scan as defined by the study site

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects undergoing high quality MRI Scans<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect High Quality MRI Data |  | Approximately 6 Weeks |
Perioperative Mechanism of Acute Kidney Injury in Cardiovascular Surgery

Study Overview
=================
Brief Summary
-----------------
Continuous observation of acute renal injury after cardiac surgery, at the same time retention of blood samples, to test indicators，and to select the research route from the clinical actual test results .

Official Title
-----------------
Preliminary Study on the Pathogenesis of Acute Kidney Injury After Cardiac Surgery

Conditions
-----------------
Pathogenesis, Acute Kidney Injury, Cardiac Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients undergoing selective cardiac surgery, aged between 18 and 80. Exclusion Criteria: Normal range of creatinine before operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of acute renal injury after cardiac surgery | The standard of acute renal injury is based on the KDIGO | 48 hours |
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Drug: Solifenacin succinate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptoms of overactive bladder Must be able to complete the micturition diary Exclusion Criteria: Pregnant or lactating Clinically significant outflow obstruction Significant post void residual urine Significant stress incontinence Urinary tract infection Chronic inflammation Bladder stones Previous pelvic radiation therapy Previous or current malignant disease of the pelvic organs Uncontrolled narrow angle glaucoma Urinary or gastric retention Electrostimulation therapy Bladder training Diabetic neuropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Solifenacin succinate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Solifenacin, tolterodine, randomized controlled trial, double-blind method
Cranberry Juice for Treatment of Urinary Tract Infections

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether daily consumption of cranberry juice lessens the symptoms and prevents the recurrence of urinary tract infections (UTIs). This study will also determine whether drinking cranberry juice for 6 months selects for less virulent bacteria in the rectal, vaginal, and urethral areas.

Detailed Description
-----------------
Participants in this study will be randomly assigned to consume either 8 ounces of cranberry juice or placebo juice twice a day for 6 months. Participants will have follow-up visits at 3 and 6 months, and whenever they experience a symptomatic episode. Urine, vaginal and rectal specimens will be taken at each visit to test for the presence of bacteria that cause urinary tract infections. Participants will complete a questionnaire at study entry, Day 3, Weeks 1 and 2, and monthly thereafter or whenever there is a recurrence of symptoms.

Official Title
-----------------
Cranberry Juice and Urinary Tract Infections

Conditions
-----------------
Urinary Tract Infections

Intervention / Treatment
-----------------
* Drug: Cranberry juice
* Dietary Supplement: Placebo cranberry juice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Culture-confirmed urinary tract infection at study start Exclusion Criteria: Other chronic disease Antibiotics within 48 hours prior to study start Hospitalization for any reason within 2 weeks prior to study start Stones in urinary tract Plans to leave Ann Arbor within 6 months after study start Allergy to cranberry or cranberry compounds Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Cranberry juice | Drug: Cranberry juice<br>* TID dosage for UTI treatment<br>|
| Placebo Comparator: 2<br>Placebo juice | Dietary Supplement: Placebo cranberry juice<br>* TID placebo dosage to match active comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Culture |  | per visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccinium macrocarpon
VIPER: Veterans Integrated Pain Evaluation Research

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to learn about the causes of different types of pain that can occur in people who have had an amputation. By gathering information through blood tests, photographs, a nerve test, and questionnaires, we hope to de-code how each individual's special characteristics affect the type and amount of pain they experience in their amputated limb.

Detailed Description
-----------------
Studies have already shown that pain following amputation might be caused by differences in a person's genes. This study may help us find out how genes affect the way you feel pain and why you may feel more or less or different kinds of pain than another person with a similar amputation. What we learn in this research study may lead to discoveries as to why some painkillers work better for some people than others.

Official Title
-----------------
VIPER: Veterans Integrated Pain Evaluation Research- Molecular Subtypes of Chronic Pain Syndromes

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female active duty military personnel age 18 years and older undergoing treatment at WRAMC and future WRNMMC with the diagnosis of post injury amputation of 1 limb, more than 3 but less than 18 months prior to enrollment. In particular, phantom limb pain patients will be included Exclusion Criteria: Severe Traumatic Brain Injury (Primary major head trauma and diagnosis of traumatic brain injury resulting in documented, permanent or prolonged cognitive deficits that would preclude participation in the study (i.e. decreased intellectual capacity, marked memory deficits, or inability to communicate verbally or in writing) Significant cognitive deficits that would preclude participation in the study. Substantial hearing loss without alternative means of communication. Documented spinal cord injury with permanent or persistent deficits. Diagnosis of fibromyalgia or other chronic pain syndrome such as chronic headaches. Evidence of ongoing tissue damage pain, infection, bone spur, or poorly fitting prosthesis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proteomics | To determine which proteins represent circulating qualitative and quantitative biomarkers of pain. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proteomics study, biomarker study of pain
Spanish Version of the Balance Evaluation Systems Test and Mini Balance Evaluation Systems Test

Study Overview
=================
Brief Summary
-----------------
This study aim to translate the BESTest and mini-BESTest to Spanish, adapt it and investigate its validity in spanish population.

Detailed Description
-----------------
To translate the BESTest and mini-BESTest to Spanish, adapt it and investigate its validity in spanish. Check its metric properties in relation to other balance tests.

Official Title
-----------------
Translation and Validation of the Spanish Version of the BESTest and Mini-BESTest

Conditions
-----------------
Balance

Intervention / Treatment
-----------------
* Behavioral: Case group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy subjects without diagnosed balance problems. - Exclusion Criteria: Diagnosed balance problems. One falling in the last three months.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: single group assignment. cross-sectional survey.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: case group<br>BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group. | Behavioral: Case group<br>* assessment of quality on posture, transfers and displacement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concurrent validity of Best test- 1 | concurrent validity of BESTest compare to other model balance tests | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychometric properties of Spanish version of BESTest. | To perform a detailed analysis of the psychometric properties of the BESTest Spanish version. | 1 year | 
| Psychometric properties of Spanish version of mini-BESTest. | To perform a detailed analysis of the psychometric properties of the mini-BESTest Spanish version. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
balance, risk of falling
Antimicrobial Resistance of Bacteria in Burn Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the resistance of pathogenic bacteria in infected tissues of burn patients to various antimicrobials and enzyme debriders.

Detailed Description
-----------------
Bacteria that is present in infected burn wounds will be isolated and identified. The isolates will be tested for resistance to commercially available antimicrobials.

Official Title
-----------------
Analyzing the Antimicrobial Resistance Profile of Bacterial Isolates Obtained From Severely Burned Patients

Conditions
-----------------
Burns

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females of any age Have open, unhealed wounds(s) that will be cultured per standard of care Subject or authorized representative provide informed consent Exclusion Criteria: Informed consent not provided or able to be obtained
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Burn Wounds<br>Patients with burn wounds | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Types of bacteria |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Burn, Antimicrobial, Bacteria, Resistance, Biofilm, Pathogen
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk

Study Overview
=================
Brief Summary
-----------------
It is the central hypothesis of the investigators study that HIV disease is a pro-inflammatory condition, and that years of inflammation result in premature aging' of the immune system (immunosenescence). Just as these changes are thought be causally associated with heart disease in the very old,the investigators postulate that these changes will be associated with early heart disease in the untreated and perhaps treated HIV disease. To address this hypothesis, the investigators will measure immunosenescence in a large cohort of patients who span the entire disease process.

Official Title
-----------------
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk

Conditions
-----------------
HIV Infection, Cardiovascular Disease, Inflammation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV controllers: positive for HIV by standard antibody serological determinations with undetectable HIV RNA level (< 75 copies RNA/mL) in absence of therapy HIV non-controllers: detectable HIV RNA levels in absence of therapy Highly active anti-retroviral therapy responders (HAART responders): on combination antiretroviral therapy with undetectable HIV RNA levels. HIV-seronegative participants will also be studied. Exclusion Criteria: Treated individuals that changed antiretroviral regimen within 12 weeks prior to study enrollment. Individuals who have started or stopped antihypertensive medication or lipid lowering medication or changed doses of these drugs within 12 weeks of the study will be excluded. As nitroglycerin is administered to assess endothelium-independent vasodilation, we also plan to exclude patients who have taken sildenafil, vardenafil, or tadalafil within 72 hours of the endothelial function study, or who are hypotensive (systolic BP <100).

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV-Infection<br>Treated HIV-infected individuals with an undetectable HIV RNA level (< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brachial artery flow-mediated dilatation |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV Infection, Endothelial function, Cardiovascular Disease, Inflammation, Antiretroviral medication, Treatment naive, Treatment experienced
Establishing a Descriptive Cohort of Patients Cared for Operation on the Spine

Study Overview
=================
Brief Summary
-----------------
This study aims to: describe the monitoring of patients treated for spinal disorders. create a comprehensive database of reliable and readily exploitable quickly to produce a library of cross publications between orthopedic surgery and neurosurgical services. This database will include clinical, functional , radiographic , educational, social and professional data. obtain a cohort of patients in the comprehensive range of spinal pathologies. standardize data collection in this cohort with similar national projects.

Conditions
-----------------
Quality of Life, Spinal Injuries, Spinal Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must be given free and informed consent and signed the consent The patient must be affiliated or beneficiary of a health insurance plan The patient is available for a 24-month follow-up The patient is at least 18 years old The patient has a symptomatic spinal pathology requiring surgical or orthopedic treatment Exclusion Criteria: The patient is under judicial protection, guardianship or curatorship The patient refuses to sign the consent It is not possible to give informed information to the patient The patient does not fluently read French. the patient is not available for a 24-month follow-ip

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life measured by the Oswestry Disability Index score |  | 24 months after surgical intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life measured by the Oswestry Disability Index score |  | 6 weeks, 12 weeks, 6 months, 12 months, 36 months, 48 months after surgical intervention |
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Study Overview
=================
Brief Summary
-----------------
Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy (28 days).

Official Title
-----------------
Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)

Conditions
-----------------
Leukemia, Lymphocytic, Chronic

Intervention / Treatment
-----------------
* Drug: forodesine hydrochloride (BCX-1777)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18 years and older Diagnosis of CLL established by peripheral blood and bone marrow examination and using the standard criteria Patients with Rai stage III or IV, or earlier stage with massive, symptomatic lymphadenopathy requiring therapy Primary resistance to fludarabine-based therapy (no complete response [CR] or partial response [PR]) or progressive disease within 6 months of response to prior fludarabine containing regimen. ECOG performance status of 0, 1, 2 or 3 Willing to take adequate contraception (i.e. latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after All investigational treatments should have been discontinued for at least 1 week prior to the initiation of the study drug. Exclusion Criteria: Pregnant or nursing Unable or unwilling to sign consent Severe, ongoing co-morbid conditions, which would preclude safe delivery of the investigational therapy Active serious infections that are not controlled by antibiotics ECOG performance status 4 Inadequate renal function: creatinine 2.0 or more unless related to the disease Inadequate liver function: bilirubin 3.0 or more, transaminases 3 x upper limit of normal or more unless related to the disease Known positive test for HIV Patients with known hepatitis B and/or hepatitis C active infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate after 2 cyclesof forodesine therapy. |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CLL, Chronic lymphocytic leukemia, leukemia, Advanced, fludarabine-refractory CLL